Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Sanofi-Aventis |
---|---|
Information provided by: | Sanofi-Aventis |
ClinicalTrials.gov Identifier: | NCT00546676 |
To determine the clinical effectiveness of telithromycin in the treatment of either CAP or AECB in a large population of ambulatory adult patients in a community-based setting.
Condition | Intervention | Phase |
---|---|---|
Community Acquired Pneumonia (CAP) Acute Exacerbation of Chronic Bronchitis (AECB) |
Drug: Telithromycin |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Canadian Multicenter, Prospective, Open Label, Non-Comparative Study of the Effectiveness and Safety of Oral Telithromycin, 800mg Once Daily in the Treatment of Either Community Acquired Pneumonia or Acute Exacerbation of Chronic Bronchitis in Ambulator |
Enrollment: | 174 |
Study Start Date: | May 2004 |
Study Completion Date: | December 2004 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Male or female subjects greater than or equal to 18 years who fulfill the clinical diagnostic criteria for outpatient treatment of one of the two following community acquired respiratory tract infections (CARTIs):
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study ID Numbers: | HMR3647A_4018 |
Study First Received: | October 18, 2007 |
Last Updated: | November 13, 2007 |
ClinicalTrials.gov Identifier: | NCT00546676 History of Changes |
Health Authority: | Canada: Health Canada |
Anti-Bacterial Agents Bronchitis, Chronic Lung Diseases, Obstructive Respiratory Tract Infections Respiratory Tract Diseases Bronchial Diseases |
Lung Diseases Bronchitis Telithromycin Pneumonia Pulmonary Disease, Chronic Obstructive |
Anti-Infective Agents Bronchial Diseases Pharmacologic Actions Telithromycin Bronchitis, Chronic Anti-Bacterial Agents Lung Diseases, Obstructive |
Respiratory Tract Diseases Respiratory Tract Infections Lung Diseases Therapeutic Uses Bronchitis Pneumonia Pulmonary Disease, Chronic Obstructive |